SSA
CRVS icon

Schonfeld Strategic Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-39,783
Closed -$127K – 2116
2025
Q1 		$127K Sell
39,783
-89,293
-69% -$421K ﹤0.01% 1997
2024
Q4 		$691K Sell
129,076
-202,284
-61% -$1.51M ﹤0.01% 1277
2024
Q3 		$1.75M Buy
+331,360
New +$1.19M 0.01% 939

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's CRVS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2025, closing a stake of 39,783 shares — an estimated $127K sold.

Schonfeld Strategic Advisors first reported a position in CRVS in Q3 2024 and held it in 3 quarters. The position peaked at $1.75M in Q3 2024. 92 funds tracked by Wall St. Rank hold CRVS as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 39,783 Corvus Pharmaceuticals shares in Q2 2025, an estimated $127K.
  • Schonfeld Strategic Advisors first reported a position in Corvus Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Corvus Pharmaceuticals position peaked at $1.75M in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.